EDOF

AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL

Retrieved on: 
Tuesday, October 10, 2023
Partnership, Walking, MINI, EDOF, Intraocular lens, Cooking, Safety, Greater, Therapy, Astigmatism, Approximation error, Marketing, Policy, Presbyopia, Patient, Reading, Automotive industry, Telescopic sight, Medical device, Steel mill, Mainland China, IOL

BEIJING, Oct. 10, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A. ("SIFI"), today announced it has entered into a licensing agreement with SIFI under which AffaMed has obtained the exclusive rights to manufacture, develop and commercialize EVOLUX®, a novel extended monofocal intraocular lens (IOL), in Greater China. During a signing ceremony held in Beijing, the CEOs of AffaMed Therapeutics and SIFI celebrated this important expansion of AffaMed's portfolio of innovative premium IOLs for the Greater China market, and the strong progress achieved by their joint venture since its inception in April 2021.

Key Points: 
  • EVOLUX® is a novel extended monofocal intraocular lens (IOL), based on a hydrophobic material and a non-diffractive profile, designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL.
  • The applied optical technology provides an improved intermediate vision maintaining a well-performing distance vision, very low pupil dependency at far and intermediate distances, and similar image contrast with different pupil dimensions.
  • In this way, the new extended monofocal IOL Evolux can help patients with their everyday activities, making everyday life easier.
  • Choosing a monofocal IOL improving intermediate vision means helping patients with their everyday activities and making their life easier.

SIFI ANNOUNCES CERTIFICATION OF WELL FUSION® ACCORDING TO EU MDR

Retrieved on: 
Wednesday, September 6, 2023
Presbyopia, MDR, Aphakia, EU, Patient, MINI, WELL, EDOF, Medical device, Telescopic sight

CATANIA, Italy, Sept. 6, 2023 /PRNewswire/ -- SIFI, a leading international eye care company, announces that the MINI WELL and MINI WELL PROXA intraocular lenses, as well as their combined use, commercially known as WELL FUSION®, are now certified for cataract surgery and refractive lens exchange, according to the European Union medical device regulation 2017/745 (MDR).

Key Points: 
  • WELL FUSION® is the first and only binocular optical system based on wavefront aberrations to correct presbyopia after removal of the natural lens.
  • CATANIA, Italy, Sept. 6, 2023 /PRNewswire/ -- SIFI, a leading international eye care company, announces that the MINI WELL and MINI WELL PROXA intraocular lenses, as well as their combined use, commercially known as WELL FUSION®, are now certified for cataract surgery and refractive lens exchange, according to the European Union medical device regulation 2017/745 (MDR).
  • "We are pleased to reach such a regulatory milestone, ensuring patients will continue to have access to WELL FUSION® beyond the regulatory transition period in Europe."
  • stated Fabrizio Chines, SIFI Chairman and CEO "The clinical evidence generated since 2021 confirmed that our pioneering and patented technology effectively delivers uninterrupted high-quality vision at all distances after cataract surgery and refractive lens exchange, meeting the stricter requirements of the EU MDR."

Johnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress

Retrieved on: 
Wednesday, August 30, 2023
Presbyopia, Johnson & Johnson Vision, Natural Resources, A4, Patient, Near-sightedness, Congress, Environment, Johnson, Element, EDOF, Small incision lenticule extraction, Ophthalmology, Cataract, Woman, Symposia, Abstract, The New Elite, Eye, Carbon, Lock (computer science), Intraocular lens, Cornea, Surgeon, SILK, Food, IIS, Recycling, Toronto Congress Centre, Astigmatism, European Society of Clinical Microbiology and Infectious Diseases, Health, Dentistry, Telescopic sight, Pharmaceutical industry, Software

LONDON, Aug. 30, 2023 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of Johnson & Johnson MedTechi, will announce the launch of a next-generation laser vision correction solution, the ELITATM Platform, at the 41st European Society of Cataract and Refractive Surgeons (ESCRS) congress, 8-12 September 2023. The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.

Key Points: 
  • The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.
  • The ELITATM Platform enables surgeons to perform refractive correction on patients with myopia, with or without astigmatism, using the new SILK (Smooth Incision Lenticule Keratomileusis) procedure.
  • The Johnson & Johnson Vision ESCRS Booth (#B202) will have live demonstration areas for surgeons to experience first-hand the ELITATM Femtosecond Laser as well as other leading Johnson & Johnson Vision products.
  • Additionally, attendees will be able to participate in the Toric VR Simulator experience alongside dry labs and meet the expert sessions at the booth and in the Johnson & Johnson Vision Lighthouse.

New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

Retrieved on: 
Saturday, May 6, 2023
Medical Devices, Health, Surgery, Research, Science, Optical, Comparison, Refractive surgery, American National Standards Institute, Cataract, ASCRS, EDOF, ANSI, American Society of Cataract and Refractive Surgery, Incidence, Intraocular lens, Patient, Annual general meeting, FDA, Society, NYSE, Telescopic sight, Medical device, Alcon, IOL

The investigator-initiated study** led by J. Morgan Micheletti, M.D., demonstrated that Clareon® and Eyhance* monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.1

Key Points: 
  • The investigator-initiated study** led by J. Morgan Micheletti, M.D., demonstrated that Clareon® and Eyhance* monofocal IOLs provide similar range of vision, including distance and intermediate visual acuity.1
    “The Eyhance monofocal IOL was introduced into our practice as a next-generation IOL offering to slightly extend the range of vision for our patients undergoing cataract surgery.
  • However, we observed that our patients' postoperative intermediate visual outcomes did not consistently demonstrate discernible improvements over other monofocal IOLs," said Dr. Micheletti, Director of Research at Berkeley Eye Center.
  • “In order to explore this further, we decided to look at real-world evidence by prospectively evaluating the vision of patients who had previously been implanted with bilateral Clareon monofocal IOLs or Eyhance IOLs.
  • The binocular defocus curves were extremely similar from +1.00 D to -3.00 D further demonstrating similar range of vision for both monofocal IOLs.

Global Intraocular Lens Market Outlook Report 2023-2028: Adoption & Penetration of Premium IOLs Gaining Momentum - ResearchAndMarkets.com

Retrieved on: 
Friday, April 21, 2023
Health, Optical, Prevalence, Toric, COVID-19, Presbyopia, Cell proliferation, Cataract, USD, Bausch & Lomb, EDOF, Hospital, Alcon, Patient, Phacoemulsification, Aspheric lens, Vance DeGeneres, Nature, Diagnosis, ZEISS, Johnson & Johnson, Ageing, Abdominal ultrasonography, Intraocular lens, Generic drug, Veterinary medicine, Retail, Telescopic sight, Adhesive, IOL

The "Intraocular Lens Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intraocular Lens Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the premium intraocular lens (IOL) market is projected to grow significantly faster as worldwide cataract procedure volumes return to pre-COVID-19 levels.
  • Vendors in the intraocular lens market are focused on using innovative technology platforms to increase the comfort and ease of use for IOLs.
  • The global intraocular lens market is concentrated in nature, with a limited number of major players accounting for commendable market shares.

Global Intraocular Lenses Market 2022 to 2027: Soaring Screen Time and Increasing Incidence of Computer Vision Syndrome Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Optical, Health, Medical Devices, Bausch & Lomb, GCC, Alcon, Intraocular lens, Johnson & Johnson, Geography, EDOF, Retail, Video game, Pharmaceutical industry, IOL

In this report, the market has been segmented based on organization size, component, provider, type, industry and geography.

Key Points: 
  • In this report, the market has been segmented based on organization size, component, provider, type, industry and geography.
  • The report provides an overview of the intraocular lens (IOL) global market and analyses market trends.
  • Using 2021 as the base year, the report provides estimated market data for the forecast period from 2022 to 2027.
  • The report estimates the global market for IOL in 2021 and provides projections for the expected market size through 2027.

Worldwide Intraocular Lenses Industry to 2027 - Increasing Demand for Ophthalmic Surgery for Vision Correction Presents Opportunities

Retrieved on: 
Tuesday, January 31, 2023
Lens (vertebrate anatomy), Intraocular lens, Johnson & Johnson, Bausch & Lomb, Geography, GCC, Alcon, EDOF, Retail, Video game, Pharmaceutical industry, IOL

DUBLIN, Jan. 31, 2023 /PRNewswire/ -- The "Intraocular Lenses: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 31, 2023 /PRNewswire/ -- The "Intraocular Lenses: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering.
  • In this report, the market has been segmented based on organization size, component, provider, type, industry and geography.
  • The report provides an overview of the intraocular lens (IOL) global market and analyses market trends.
  • Using 2021 as the base year, the report provides estimated market data for the forecast period from 2022 to 2027.

Bausch + Lomb Acquires AcuFocus, Inc.

Retrieved on: 
Tuesday, January 17, 2023
Medical Supplies, Medical Devices, Health, Surgery, General Health, Optical, Cataract, Severe cognitive impairment, Ageing, Presbyopia, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Growth, EDOF, Patient, Bausch & Lomb, Physician, Dioptre, Astigmatism, Multimedia, Telescopic sight, Pharmaceutical industry, IOL

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.
  • Known as the IC-8 IOL in global markets, this IOL is available in select markets across Europe, as well as in Australia, New Zealand and Singapore.
  • Some available presbyopia-correcting IOLs have complex optics that split, shift or stretch light to provide clear vision at more than one discrete focal point.
  • “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”

Johnson & Johnson Vision Introduces All Purpose EDOF, TECNIS Symfony OptiBlue IOL, the Latest PC-IOL Powered by InteliLight Technology

Retrieved on: 
Wednesday, September 28, 2022
Storm, Adult, American Academy, Lens, Aphakia, Cataract, American Academy of Ophthalmology, Lists of diseases, Ophthalmology, Patient, Clinical trial, U.S. Securities and Exchange Commission, Exercise, Technology, Perception, Muscular dystrophy, Biostatistics, Risk, Temperature, EDOF, Amblyopia, Annual general meeting, Life, Rotation, GLARE, Cerebral edema, Johnson & Johnson, Visual acuity, Annual report, Direction, Doctor of Philosophy, Surgeon, Behavior, Color, MD, Emmetropia, Language interpretation, Medtech, IOL, Presbyopia, Severe cognitive impairment, EMEA, Security (finance), Light, Endophthalmitis, Health, AAO, Vision, LinkedIn, Johnson & Johnson Vision, Astigmatism, Private Securities Litigation Reform Act, Eye, Use, Diagnosis, Fine chemical, Telescopic sight, Pharmaceutical industry, Facebook

IRVINE, Calif., Sept. 28, 2022 /PRNewswire/ -- Johnson & Johnson Vision,** a global leader in eye health and part of Johnson & Johnson MedTech,*** today announced availability of our presbyopia-correcting intraocular lens (PC-IOL) powered by InteliLight technology https://www.jnjvisionpro.com/intelilight, TECNIS Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins TECNIS Synergy IOL, a high-performance hybrid lens designed for spectacle independence****, in the InteliLight portfolio. These two complementary products deliver superior* contrast and low-light performance across the PC-IOL category.1,2,3 The InteliLight portfolio will be on display at the 2022 American Academy of Ophthalmology's Annual Meeting (AAO) in Chicago, Sept. 30-Oct. 3.

Key Points: 
  • To learn more about the InteliLight portfolio, please visit https://www.jnjvisionpro.com/intelilight in the U.S.
    At Johnson & Johnson Vision, part of Johnson & Johnson MedTech**, we have a bold ambition: to change the trajectory of eye health worldwide.
  • Visit us at jjvision.com , follow @JNJVision on Twitter , Johnson & Johnson Vision on LinkedIn , and @JNJVision on Facebook .
  • Neither Johnson & Johnson Vision, the Johnson & Johnson MedTech Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
  • **Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Retrieved on: 
Wednesday, September 14, 2022
Medical Supplies, Health, Medical Devices, Hospitals, Surgery, Health Technology, General Health, Laparoscopy, Observation, Software, Olympus, 3D, Efficiency, Gynaecology, Movement, Olympus Corporation, Twitter, Endoscopy, Sale, EDOF, Sony, Blood, Representative, Corporation, Google Images, Patient, Cholecystectomy, Technology, Quality of life, Standard of care, General surgery, EMEA, ENT, Surgeon, Surgical Endoscopy, HCPS, NBI, Hospital, Multimedia, Urology, Medical device

View the full release here: https://www.businesswire.com/news/home/20220913005632/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220913005632/en/
    Surgical visualization platform VISERA ELITE III (Photo: Business Wire)
    With VISERA ELITE III, we provide a best-in-class surgical visualization platform designed for multiple medical specialties and configurations, allowing HCPs to fully focus on the patient during surgery.
  • By incorporating the technologies of its predecessors VISERA ELITE II and VISERA 4K UHD into one platform, VISERA ELITE III enhances the quality of endoscopic surgery, contributes to improved efficiency in the operating room, and hereby elevates the standard of care, said Kanichi Matsumoto, Global Head of Surgical Endoscopy at Olympus.
  • VISERA ELITE III system integrates the 3D and infrared1 imaging functions from VISERA ELITE II, and the 4K imaging function from VISERA 4K UHD system.
  • In developing VISERA ELITE III, Sony Olympus Medical Solutions, a joint venture company of Sony and Olympus, optimized each technology and image processing function specifically for medical applications to create the most advanced, open, and versatile surgical visualization platform Olympus has ever brought to market.